Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. ASH 2021;Abstract 35.
Daver N et al. Phase I/II study of azacitidine (aza) with venetoclax (ven) and magrolimab (magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.
Grenet J et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia. ASH 2021;Abstract 32.
Jaggers JL et al. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. J Geriatric Oncol 2021;12(2):235-8. Abstract
Jayani RV, Olin RL. Physically “fit” for allogeneic stem cell transplant?Bone Marrow Transplant 2021;56(11):2628-9. Abstract
Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: Geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol 2021;8(22):e853-61. Abstract
Lachowiez C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. ASH 2021;Abstract 701.
Matthews A et al. Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adult acute myeloid leukemia. ASH 2021;Abstract 795.
Mishra A et al. Breaking the age barrier: Physicians’ perceptions of candidacy for allogeneic hematopoietic cell transplantation in older adults. Transplant Cell Ther 2021;27(7):617.e1-7. Abstract
Patel PA et al. Ivosidenib (ivo) in combination with azacitidine (aza) in newly diagnosed (nd) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the Beat AML Master trial. ASH 2021;Abstract 875.
Short NJ et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: Results from a phase I/II study. ASH 2021;Abstract 696.
Sugidono M et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults. Transplant Cell Ther 2021;27(4):344.e1-5. Abstract
Szewczyk NA et al. Feasibility and implementation of a multimodal supportive care program to improve outcomes in older patients undergoing allogeneic stem cell transplantation. Transplant Cell Ther 2021;27(12):1008-14. Abstract
Traer E et al. Gilteritinib (gilt) monotherapy with addition of decitabine (dec) in non-responders in older newly diagnosed (nd) FLT3 mutated acute myeloid leukemia (AML) patients having high and low variant allele frequency (VAF): A phase 2/1b sub-study of the Beat AML Master trial. ASH 2021;Abstract 1277.
Wang ES et al. Phase 3, open-label, randomized study of gilteritinib and azacitidine vs azacitidine for newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. ASH 2021;Abstract 700.
Wang J et al. Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: A phase 3, randomized, multicenter, open-label trial in Asia. ASH 2021;Abstract 695.
Yilmaz M et al. Quizartinib (quiz) with decitabine (dac) and venetoclax (ven) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) – RAS/MAPK mutations continue to drive primary and secondary resistance. ASH 2021;Abstract 370.